Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. Export

@article{citeulike:3731380, abstract = {PURPOSE: Since chronic inflammation contributes to tumorigenesis, we hypothesized that the risk and clinical outcome of bladder cancer (BC) might be modulated by genetic variations in inflammation genes. METHODS: Using the TaqMan method, we genotyped single nucleotide polymorphisms in interleukin (IL) -6 (-174 G-->C), IL-8 (-251 T-->A), tumor necrosis factor-alpha (TNF-alpha; -308 G-->A), and peroxisome proliferator-activated receptor gamma (PPARG; Pro12Ala), and determined their associations with BC initiation and clinical outcome. RESULTS: We found that the IL-6 variant genotype (C/C) was associated with an increased BC risk (OR, 1.77; 95\% CI, 1.25 to 2.51). There were joint effects between the variant IL-6 genotypes and smoking status, and between the variant genotypes of IL-6 and other genes. To assess effect on recurrence, we grouped non-muscle-invasive BC patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, induction BCG (iBCG), and maintenance BCG (mBCG). In the Cox proportional hazards model, the variant IL-6 genotype was associated with an increased recurrence risk (hazard ratio [HR], 4.60; 95\% CI, 1.24 to 17.09) in patients receiving mBCG. The variant PPARG genotype was associated with a reduced recurrence risk (HR, 0.41; 95\% CI, 0.20 to 0.86) among untreated patients. In patients with non-muscle-invasive BC, the variant IL-6 genotype was associated with an increased progression risk (HR, 1.88; 95\% CI, 0.80 to 4.11). In patients with invasive BC, variant IL-6 was associated with improved 5-year overall and disease-specific survival (HR, 0.43; 95\% CI, 0.19 to 0.94 and HR, 0.39; 95\% CI, 0.15 to 1.00, respectively). CONCLUSION: Inflammation gene polymorphisms are associated with modified BC risk, treatment response, and survival.}, author = {Leibovici, D. and Grossman, H. B. and Dinney, C. P. and Millikan, R. E. and Lerner, S. and Wang, Y. and Gu, J. and Dong, Q. and Wu, X.}, citeulike-article-id = {3731380}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2005.01.598}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16110031}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16110031}, doi = {10.1200/JCO.2005.01.598}, issn = {0732-183X}, journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, keywords = {background, balance, bladder, cancer, polymorphisms, superlist, survival, th1, th2, thelist}, month = {August}, number = {24}, pages = {5746--5756}, posted-at = {2008-12-01 01:50:34}, priority = {2}, title = {Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.}, url = {http://dx.doi.org/10.1200/JCO.2005.01.598}, volume = {23}, year = {2005} }

TY - JOUR ID - citeulike:3731380 L3 - citeulike-article-id:3731380 N2 - PURPOSE: Since chronic inflammation contributes to tumorigenesis, we hypothesized that the risk and clinical outcome of bladder cancer (BC) might be modulated by genetic variations in inflammation genes. METHODS: Using the TaqMan method, we genotyped single nucleotide polymorphisms in interleukin (IL) -6 (-174 G-->C), IL-8 (-251 T-->A), tumor necrosis factor-alpha (TNF-alpha; -308 G-->A), and peroxisome proliferator-activated receptor gamma (PPARG; Pro12Ala), and determined their associations with BC initiation and clinical outcome. RESULTS: We found that the IL-6 variant genotype (C/C) was associated with an increased BC risk (OR, 1.77; 95% CI, 1.25 to 2.51). There were joint effects between the variant IL-6 genotypes and smoking status, and between the variant genotypes of IL-6 and other genes. To assess effect on recurrence, we grouped non-muscle-invasive BC patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, induction BCG (iBCG), and maintenance BCG (mBCG). In the Cox proportional hazards model, the variant IL-6 genotype was associated with an increased recurrence risk (hazard ratio [HR], 4.60; 95% CI, 1.24 to 17.09) in patients receiving mBCG. The variant PPARG genotype was associated with a reduced recurrence risk (HR, 0.41; 95% CI, 0.20 to 0.86) among untreated patients. In patients with non-muscle-invasive BC, the variant IL-6 genotype was associated with an increased progression risk (HR, 1.88; 95% CI, 0.80 to 4.11). In patients with invasive BC, variant IL-6 was associated with improved 5-year overall and disease-specific survival (HR, 0.43; 95% CI, 0.19 to 0.94 and HR, 0.39; 95% CI, 0.15 to 1.00, respectively). CONCLUSION: Inflammation gene polymorphisms are associated with modified BC risk, treatment response, and survival. IS - 24 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology SN - 0732-183X EP - 5756 TI - Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. VL - 23 SP - 5746 KW - background KW - balance KW - bladder KW - cancer KW - polymorphisms KW - superlist KW - survival KW - th1 KW - th2 KW - thelist AU - Leibovici, D AU - Grossman, HB AU - Dinney, CP AU - Millikan, RE AU - Lerner, S AU - Wang, Y AU - Gu, J AU - Dong, Q AU - Wu, X PY - 2005/08/20/ UR - http://dx.doi.org/10.1200/JCO.2005.01.598 ER -